| European Case Law Identifier: | ECLI:EP:BA:2018:T214513.20180412 | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Date of decision: | 12 April 2018 | ||||||||
| Case number: | T 2145/13 | ||||||||
| Application number: | 03779091.2 | ||||||||
| IPC class: | A61K 39/395 G01N 33/53 |
||||||||
| Language of proceedings: | EN | ||||||||
| Distribution: | D | ||||||||
| Download and more information: |
|
||||||||
| Title of application: | Methods for treating post-surgical pain by administering an antibody against nerve growth factor and compositions containing the same | ||||||||
| Applicant name: | Rinat Neuroscience Corp. | ||||||||
| Opponent name: | Regeneron Pharmaceuticals, Inc. Sanofi (opposition withdrawn) |
||||||||
| Board: | 3.3.04 | ||||||||
| Headnote: | - | ||||||||
| Relevant legal provisions: |
|
||||||||
| Keywords: | Novelty - main request (no) | ||||||||
| Catchwords: |
- |
||||||||
| Cited decisions: |
|
||||||||
| Citing decisions: |
|
||||||||
Source: http://www.epo.org/law-practice/case-law-appeals/recent/t132145eu1.html
Date retrieved: 17 May 2021